New THC vapor self-administration paper with @CassieMoorePhD
Published in @PsychopharmEBPS
as part of a special issue honoring my former mentor Klaus Miczek.
Free access using this author link:
https://t.co/wpFttswXAb
No adverse events.
⬇️self-reported ratings of Jittery and Actrive at 50 mg
⬇️Calm at 100 mg
⬆️Appetite associated ith 200 mg of CBG.
Pharmacokinetics were dose-orderly
Overall CBG was well-tolerated
The CBG story continues. Here is the latest study from our group @jhucsl
Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults. https://t.co/WjxtyRUmsG
No adverse events
⬇️self-reported ratings of Jittery and Actrive at 50 mg
⬇️Calm at 100mg..,
Ever wonder about how cannabigerol (CBG) may affect focus? A new study examining high-dose oral CBG administration shows measurable deficits in sustained attention in rats. Learn more here:
https://t.co/iUcwt9xEXl
2/2 He shaped my thinking about behavioral pharmacology and how to systematically study drug reinforcement, the discriminative stimulus effects of drugs and the impact of chronic drug use. He was far more than just the leader of the psychedelics renaissance.
Roland Griffiths was my post-doctoral Mentor. He led the field in pharmacology research on caffeine and "club drugs" long before he began his work on psilocybin. People forget his other contributions. This article finally highlights some of this work. https://t.co/6AOGZbW8MO
Check out our new article about preclinical models of cannabis use - we incorporate new data from vapor models & discuss strategies for building on and innovating animal models of CUD. Thanks to co-authors @EliseWeertsPhD, @MegHaneyPhD & @magbedillion! https://t.co/peT6PrQXrM
Our lab's very own Dr. Vandrey was featured on the CannMed Coffee Talk podcast this week! He discussed the National Cannabis Study, which is gathering new information about the health outcomes of medicinal cannabis from people who use it. Tune in below: https://t.co/8IwENFrBKK
Check out this new review from @magbedillion and our amazing collaborators at Johns Hopkins. Where are we in developing medications to treat CUD and what do we need to do to move the needle? Hint: Maybe listen a bit to patients, many of whom are not interested in abstinence.
Our new review "Prenatal cannabinoid exposure and the developing brain: evidence of lasting consequences in preclinical rodent models" led by @BryanJenkinsPhD with Lauren Jantzie is out.
FREE access via this link: https://t.co/S4nXgTgjWX...
Amazing work by DBB's @BryanJenkinsPhD on summarizing the effects of prenatal cannabinoids on the brain and behavior! Online today - in NBBR @EliseWeertsPhD https://t.co/B4A2uVqzHw
One of my favorite aspects of science is getting to play in the sandbox with friends & colleagues and seeing the integration of different research streams come together. I am very privileged to have gotten to go on this scientific journey with @sjo09@SLLesuis and @Franklandlab